Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.78 |
| ▸ | PDE1A | P54750 | 2/20 | 0.74 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927931 | 1.00 | PDE4A (0.78) | PDE4APDE1APDE1B | |
| SCHEMBL2510080 | 1.00 | PDE4A (0.78) | PDE4APDE1APDE1B | |
| SCHEMBL2512525 | 1.00 | PDE4A (0.78) | PDE4APDE1APDE1B | |
| SCHEMBL2510081 | 0.91 | PDE4A (0.75) | PDE4APDE1APDE1B | |
| SCHEMBL14243423 | 0.89 | PDE4A (0.85) | PDE4APDE1APDE1B | |
| SCHEMBL14158310 | 0.89 | PDE4A (0.85) | PDE4APDE1APDE1B | |
| SCHEMBL29790189 | 0.89 | PDE4A (0.85) | PDE4APDE1APDE1B | |
| SCHEMBL2472569 | 0.86 | PDE1A (0.87) | PDE4APDE1APDE1B | |
| SCHEMBL18928137 | 0.86 | PDE1A (0.87) | PDE4APDE1APDE1B | |
| SCHEMBL2509883 | 0.85 | PDE4A (0.79) | PDE4APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11291666-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210213018-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-09-17 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10398698-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180177782-A9 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180177782-A9 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180000825-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-2367429-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160083390-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150374699-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150374699-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150038474-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-02-05 | — | — | US | disclosed |
| US-20140005155-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC (US) | 2014-01-02 | — | — | US | disclosed |
| US-8536159-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110245214-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000825-A1 | NOVEL USES | PDE2A, PDE5A, PDE3A | PDE4A 6/4885PDE1A 13/4885PDE1B 21/4885 |
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | GAP43, NGF, CHAT | PDE4A 236/4885PDE1A 1787/4885PDE1B 1519/4885 |
| US-20150038474-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-10398698-B2 | Uses | PDE5A, PDE2A, PDE3A | PDE4A 6/4885PDE1A 19/4885PDE1B 29/4885 |
| US-20150374699-A1 | NOVEL USES | PDE2A, PDE5A, PDE3A | PDE4A 6/4885PDE1A 13/4885PDE1B 21/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE4A 9/4885PDE1A 13/4885PDE1B 22/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | PDE4A 8/4885PDE1A 10/4885PDE1B 17/4885 |
| US-20210213018-A1 | NOVEL USES | PDE2A, PDE4A, PDE1A | PDE4A 2/4885PDE1A 3/4885PDE1B 8/4885 |
| US-11291666-B2 | Uses | PDE2A, PDE3A, PDE5A | PDE4A 4/4885PDE1A 7/4885PDE1B 13/4885 |
| US-20160083390-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20140005155-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20110245214-A1 | ORGANIC COMPOUNDS | CYP3A7, TPMT, UGT2B7 | PDE4A 2270/4885PDE1A 4752/4885PDE1B 4738/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE4A 9/4885PDE1A 13/4885PDE1B 22/4885 |
| US-20180177782-A9 | NOVEL USES | PDE2A, PDE5A, PDE3A | PDE4A 6/4885PDE1A 13/4885PDE1B 21/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PDE4A 10/4885PDE1A 13/4885PDE1B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.